一个随机临床试验的 bermekimab治疗临床改善系统性硬化症
Nicky Solomonidi1, Panayiotis G Vlachoyiannopoulos2, Maria Pappa2
14th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
iScience
|September 8, 2023
概括
伯梅基马布是一种互白素-1α抑制剂,在治疗系统性硬化症 (SSc) 方面表现有前途. 该研究发现,me bermekimab显著改善了SSc患者的肺功能,并减少了炎症标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 在全身性硬化 (SSc) 组织中观察到高的互白素-1α (IL-1α) 水平.
- 抑制IL-1α是一种潜在的SSc治疗策略.
研究的目的:
- 评估me bermekimab,一种阻断IL-1α的单克隆抗体,在SSc.患者中的安全性和有效性.
- 为了验证治疗反应评估的新型"SSc进展抑制得分".
主要方法:
- 一个双盲,安慰剂控制的研究设计.
- 包括经过验证的"SSc进展抑制得分",CRISS指数和修改的CRISS指数.
- 安全性,疗效和生物标志物变化的评估,包括IL-1α和TNF的产生和CD42/Cd62-血小板计数.
主要成果:
- 主要终点得到了80%的meqerimab治疗患者,而安慰剂治疗患者的20% (p=0.023).
- 在一氧化碳肺部扩散能力方面,发现了显著的改善.
- 观察到单核细胞IL-1α和TNF的产生减少,CD42/Cd62血小板数量减少.
结论:
- 柏梅基马布作为治疗全身性硬化症的有效性和安全性有希望.
- 该研究表明, bermekimab 可能调节关键的炎症途径,与SSc进展有关.
相关概念视频
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168


